Clinical Trials Logo
  1. Home
  2. Ectopic Pregnancy
  3. NCT05198141

Evaluation of Different Doses of Letrozole in Ectopic Pregnancy — letrezole  

Ectopic Pregnancy Clinical Trial

Official title:
Evaluation of Different Doses of Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy

Clinical Trial Summary

The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg letrozole.

Clinical Trial Description

Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction of abortion Sixty patients with undisturbed ectopic pregnancy were classified into three equal groups. Group I: The control group that contained women who were undergoing laparoscopic salpingectomy, Group II: Patients who received letrozole (5 mg d-1) for 10 d, and Group III: Patients who received letrozole (10 mg d-1) for 10 d. After that, the human chorionic gonadotropin (β-hCG) levels were determined for the first day and after 11 d of treating. letrozole (10 mg d-1) markedly reduced the receptors of estrogen and progesterone, and subsequent vascular endothelial growth factor signals, resulting in marked apoptosis in the placenta tissue. The utilization of letrozole at a dose of 10 mg d-1 for inducement of abortion typically results in a substantial high-successful rate without any severe side effects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05198141
Study type Interventional
Source Zagazig University
Contact
Status Completed
Phase Phase 4
Start date December 15, 2020
Completion date January 1, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02995356 - Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy
Completed NCT01876004 - Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy Phase 4
Not yet recruiting NCT05039853 - Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task N/A
Completed NCT00194207 - Risk Factors of Ectopic Pregnancy N/A
Completed NCT00827970 - Randomized Population-Based Study on Chlamydia Trachomatis Screening N/A
Recruiting NCT05374720 - Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy N/A
Completed NCT03894735 - Vitamin D in Ectopic Pregnancies
Recruiting NCT01860690 - BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success Phase 4
Recruiting NCT04176549 - Assessment of Biomarkers in Ectopic Pregnancy
Not yet recruiting NCT05890066 - Single-port Versus Multi-port Laparoscopic Surgery for Ectopic Pregnancy N/A
Completed NCT01855568 - Methotrexate Treatment for Ectopic Pregnancy Phase 3
Not yet recruiting NCT04308343 - The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy N/A
Recruiting NCT06354439 - Use of Letrozole for Ectopic Pregnancy Phase 4
Not yet recruiting NCT06300333 - Treatment of Ectopic Pregnancy by Low Dose of Methotrexate
Completed NCT00194272 - Two-Dose Methotrexate for Ectopic Pregnancy Phase 3
Enrolling by invitation NCT03579550 - Hysteroscopic Metroplasty in Unexplained Infertile Women With Dysmorphic Uterus N/A
Completed NCT05446012 - Relationship Between Ectopic Pregnancy and Thyroid Disorders
Completed NCT00194168 - Ectopic Pregnancy Biomarkers N/A
Completed NCT02152696 - Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location Phase 3
Not yet recruiting NCT04975984 - Expectant Management of Ectopic Pregnancy